NCT07297940招募中1 期
An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 in Healthy Subjects at Fasting State
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- AUCt
研究概览
简要总结
This clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 at fasting state.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers
- •BMI between 18 and 30 kg/m2
- •Body weight: Male ≥ 50kg, Female ≥ 45kg
- •Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study
排除标准
- •Subjects with clinically significant medical history
- •Subjects with history of drug abuse or addicted
- •Subjects with allergy or drug hypersensitivity
研究组 & 干预措施
Sequence A
Experimental
干预措施: DA-1229_01 (Drug)
Sequence A
Experimental
干预措施: DA-1229_01-R (Drug)
Sequence B
Experimental
干预措施: DA-1229_01 (Drug)
Sequence B
Experimental
干预措施: DA-1229_01-R (Drug)
结局指标
主要结局
AUCt
时间窗: pre-dose~72 hours post-dose
Area Under the Curve
Cmax
时间窗: pre-dose~72 hours post-dose
Maximum Plasma Concentration
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.NCT07267221Daewoong Pharmaceutical Co. LTD.36
招募中
1 期
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid TumorNCT07275242Suzhou Suncadia Biopharmaceuticals Co., Ltd.107
招募中
1 期
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal TumorsNCT07263594DualityBio Inc.127
招募中
1 期
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18
招募中
2 期
A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other
types of cancers of the skin and mucosal membranes in the body.2023-509451-14-00Novartis Pharma AG27